Date of Presentation
5-4-2023 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
Autism Spectrum Disorder (ASD) and congenital heart defects (CHD) are conditions that both confer an immense increase in standard of care, and utilization of medical resources addressing comorbidities. One shared symptom that has been consistently cited is inflammation. This review sought to explore the levels of Tumor Necrosis Factor-πͺ (TNF-πͺ) and Interleukin-6 (IL-6) between patients diagnosed as having either ASD or CHD. By compiling published data containing the mean values of these two inflammatory markers within these populations, it was shown that while both have significantly elevated levels compared to a phenotypically normal demographic, there is no significant difference between IL-6 levels in ASD vs. CHD patients. However, there are significantly higher levels of TNF-πͺ in CHD patients compared to ASD patients. Understanding the relationship of inflammatory markers would help guide better treatments and outcomes in ASD population, especially to those with CHD.
Keywords
Autism Spectrum Disorder, Congenital Heart Defect, Tumor Necrosis Factor-alpha, Interleukin-6, Biomarkers, Epidemiologic Methods
Disciplines
Analytical, Diagnostic and Therapeutic Techniques and Equipment | Cardiology | Cardiovascular Diseases | Clinical Epidemiology | Communication Sciences and Disorders | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Medicine and Health Sciences | Social and Behavioral Sciences
Document Type
Poster
Included in
Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Cardiology Commons, Cardiovascular Diseases Commons, Clinical Epidemiology Commons, Communication Sciences and Disorders Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Social and Behavioral Sciences Commons
Inflammatory Marker Levels among Patients Diagnosed with Autism Spectrum Disorder and Congenital Heart Defects
Autism Spectrum Disorder (ASD) and congenital heart defects (CHD) are conditions that both confer an immense increase in standard of care, and utilization of medical resources addressing comorbidities. One shared symptom that has been consistently cited is inflammation. This review sought to explore the levels of Tumor Necrosis Factor-πͺ (TNF-πͺ) and Interleukin-6 (IL-6) between patients diagnosed as having either ASD or CHD. By compiling published data containing the mean values of these two inflammatory markers within these populations, it was shown that while both have significantly elevated levels compared to a phenotypically normal demographic, there is no significant difference between IL-6 levels in ASD vs. CHD patients. However, there are significantly higher levels of TNF-πͺ in CHD patients compared to ASD patients. Understanding the relationship of inflammatory markers would help guide better treatments and outcomes in ASD population, especially to those with CHD.